Apart from isolated reports of response to MET tyrosine kinase inhibitors (TKIs)13, 14, 15 or mechanism of acquired resistance to EGFR‐TKIs,16 current knowledge regarding MET fusions is mostly derived from three studies, which identified 2 (0.59%, 2/337) MET fusions in lung adenocarcinoma,17 1 (0.04%, 1/2410)18 and 15 (0.26%, 15/5695) fusions involving the MET kinase domain (KD) in non‐small cell lung cancer (NSCLC), respectively.19 The gene discussed is MET; the disease is non-small cell lung carcinoma.